Acumen Pharmaceuticals Expects Phase II Alzheimer's Trial Results in November 2026
Acumen Pharmaceuticals (ABOS) is approaching a critical clinical milestone with the expected announcement of top-line results from its Phase II ALTITUDE-AD trial for sabirnetug in November 2026. The drug candidate aims to neutralize toxic amyloid beta oligomers to slow cognitive decline in Alzheimer's patients, potentially paving the way for a single confirmatory Phase III registration trial. Financially, the company reported $79 million in cash and marketable securities at the end of Q3 2026, which management expects will fund operations into early 2027. Additionally, Acumen's enhanced brain delivery (EBD) platform showed significant preclinical success, with its lead candidate ACU-401 achieving up to a 40-fold increase in brain exposure during primate studies, supporting future regulatory filings for human testing in mid-2027.
Tickers: $ABOS
Topics: Alzheimer's Disease Biotechnology Clinical Trials Earnings Call